COMPANY

Karamedica

HQ: Raleigh, NC source · karamedica.com ↗ · Southeast

Karamedica is focused on developing chitosan for clinical use as an implantable hemostatic device for controlling bleeding during surgery and a drug delivery vehicle for both superficial bladder cancer and cerebral amyloid angiopathy (CAA). From company website Source · Oct 13, 2026

Keywords: surgery

Profile checked Oct 10, 2026

4NIH grants

NIH awards 4

Annual award amounts. Total $3.1M.

May 25, 2021 NIH award 5R44AG059478-04 FY2021: $1,119,539 awarded for that fiscal year; activity R44 (SBIR); PI KIRSCH, WOLFF M.; recipient as written: KARAMEDICA, INC., RALEIGH, NC. Microparticle Therapy for Cerebral Amyloid Ang source ↗
Sep 17, 2020 NIH award 2R44AG059478-03 FY2020: $1,380,461 awarded for that fiscal year; activity R44 (SBIR); PI KIRSCH, WOLFF M.; recipient as written: KARAMEDICA, INC., RALEIGH, NC. Microparticle Therapy for Cerebral Amyloid Ang source ↗
Jan 31, 2019 NIH award 5R43AG059478-02 FY2019: $225,230 awarded for that fiscal year; activity R43 (SBIR); PI KIRSCH, WOLFF M.; recipient as written: KARAMEDICA, INC., RALEIGH, NC. Microparticle Therapy for Cerebral Amyloid Angio source ↗
Apr 23, 2018 NIH award 1R43AG059478-01 FY2018: $378,841 awarded for that fiscal year; activity R43 (SBIR); PI KIRSCH, WOLFF M.; recipient as written: KARAMEDICA, INC., RALEIGH, NC. Microparticle Therapy for Cerebral Amyloid Angio source ↗

Connect

Contact page